Soluble PCSK9 Inhibition: Indications, Clinical Impact, New Molecular Insights and Practical Approach-Where Do We Stand? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37109259/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: Several clues suggest that regulation of PCSK9 represents a cornerstone of cardiovascular prevention, partly because of some pleiotropic effects attributed to these newly developed drugs. New mechanisms of PCSK9 regulation are being explored, and further efforts need to be put in place to reach patients with these new...
Share
Bruton's Tyrosine Kinase inhibition by Acalabrutinib does not affect early or advanced atherosclerotic plaque size and morphology in Ldlr-/- mice
Source : https://www.sciencedirect.com/science/article/pii/S1537189123000320?via=ihub
In human plaques, BTK is mainly expressed in mast cells, B cells and myeloid cells. * Acalabrutinib dose-dependently inhibits bone marrow-derived mast cell activation. * Acalabrutinib treatment does not affect...
Conclusions/Relevance: Conclusively, BTK inhibition by Acalabrutinib alone did neither affect either mast cell activation nor early- and advanced atherosclerosis, despite the effects on follicular B cell maturation.
Share
Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
Source : https://academic.oup.com/eurheartjsupp/article/25/Supplement_B/B55/7135794?login=false
Coronary artery disease remains a major cause of death in the developed world, although many improvements in its prevention and management. Acute coronary syndrome (ACS) [which includes unstable angina, non-ST-segment-elevation...
Conclusions: The benefit of intensive LDL-C lowering to reduce cardiovascular risk is recognized in international guidelines in patients after an ACS. Indeed, ∼20% of ACS survivors experience a subsequent ischaemic cardiovascular event within 24 months and 5-year mortality ranges from 19% to 22%. The risk reduction management of patients...
Share
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference - Current Atherosclerosis Reports
Source : https://link.springer.com/article/10.1007/s11883-023-01103-4
Purpose of Review To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2023 American College of Cardiology (ACC) conference. Recent findings The CLEAR outcomes randomized control...
Summary: The late-breaking clinical science presented at the 2023 conference of the ACC paves the way for an evidence-based alternative to statin therapy and provides data on several common clinical scenarios encountered in daily practice.
Share
Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up
Source : https://academic.oup.com/ehjopen/article/3/2/oead035/7107070?login=false
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein like particle containing apolipoprotein B covalently linked to a carbohydrate-rich protein termed apolipoprotein(a) [apo(a)]. Mechanistic and epidemiologic studies indicate that Lp(a) levels are significantly...
Conclusion: This study demonstrated that Lp(a) levels in individuals with acute MI are significantly higher six months after the initial event. Therefore, a single measurement of Lp(a) in the peri-infarction setting is not sufficient to predict the Lp(a)-associated CAD risk in the post-infarction period.
Share